# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jesse Owens (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML042-SYN-TD
- Date: 1979-08-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield-Arroyo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review after three cycles: restaging CT and the decision for surgery. **S**

## History of present illness

Mr. Owens returns three weeks after his third cycle. The cold he had at the sick visit cleared in a week, and the third cycle went ahead on schedule. Restaging CT five days ago shows the nodule shrunk from 2.9 to 1.3 cm and the interlobar node from 1.6 to 0.8 cm, with nothing new. The thoracic surgeon has booked a thoracoscopic left upper lobectomy in two weeks. He finished 16 prehabilitation sessions and walks 3 km again. He has not smoked for nine weeks. He feels a little more tired than usual, without cold intolerance, weight gain or constipation. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Restaging CT | Partial response: primary 1.3 cm (from 2.9), node 0.8 cm (from 1.6); no new disease |
| Planned operation | Thoracoscopic left upper lobectomy with lymph node dissection in two weeks |
| Tobacco | Abstinent nine weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Slightly more tired than usual; weight 75.2 kg; no fever |
| Respiratory | Negative | Cough gone since the cold cleared; no breathlessness |
| Endocrine | Negative | No cold intolerance, weight gain or constipation |
| Gastrointestinal | Negative | No diarrhea or nausea |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood good; PHQ-2 1 |

6 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet by mouth twice daily after food, for 12 weeks and then a further 12 weeks to prevent relapse **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 97% on room air; weight 75.2 kg; BMI 23.7 kg/m². All vital signs are synthetic.

Hemoglobin: 12.8 g/dL (low); White cell count: 6.2 10*3/uL; Absolute neutrophil count: 3.6 10*3/uL; Platelets: 188 10*3/uL; Sodium: 138 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.1 mg/dL; eGFR (CKD-EPI 1974): 74 mL/min/1.73 m²; Glucose: 95 mg/dL; Calcium: 9.3 mg/dL; Albumin: 4 g/dL; ALT: 31 U/L; AST: 27 U/L; Alkaline phosphatase: 90 U/L; Total bilirubin: 0.6 mg/dL; TSH: 6.8 mIU/L (high); Free T4: 1 ng/dL; Morning cortisol: 12.9 ug/dL; PHQ-2: 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 15.1 g/dL at baseline, 12.8 g/dL (low) at this visit **S**
- White cell count: 8.4 10*3/uL at baseline, 6.2 10*3/uL at this visit **S**
- Platelets: 262 10*3/uL at baseline, 188 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 1 mg/dL at baseline, 1.1 mg/dL at this visit **S**
- eGFR (CKD-EPI 1974): 84 mL/min/1.73 m² at baseline, 74 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 95 mg/dL at this visit **S**
- Calcium: 9.4 mg/dL at baseline, 9.3 mg/dL at this visit **S**
- Albumin: 4.2 g/dL at baseline, 4 g/dL at this visit **S**
- ALT: 22 U/L at baseline, 31 U/L at this visit **S**
- AST: 21 U/L at baseline, 27 U/L at this visit **S**
- Alkaline phosphatase: 84 U/L at baseline, 90 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.6 mg/dL at this visit **S**
- PHQ-2: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 75.2 kg; blood pressure 124/76, pulse 72; oxygen saturation 97 percent |
| Neck | Thyroid not enlarged or tender |
| Respiratory | Clear throughout |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Reflexes normal; no tremor |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Left upper lobe adenocarcinoma, stage IIB, after three cycles of chemoimmunotherapy** (C34.12). Partial response with no new disease; he remains a good candidate for lobectomy, with lung function well above the thresholds and better exercise tolerance after prehabilitation. Mild anemia (hemoglobin 12.8) from chemotherapy needs no treatment before surgery. **S**
   - Thoracoscopic left upper lobectomy with systematic mediastinal and hilar lymph node dissection in two weeks.
   - Folic acid stops today, three weeks after the last pemetrexed.
2. **Raised TSH on nivolumab**. TSH 6.8 with a normal free T4 (1.0) and no symptoms: subclinical thyroiditis, grade 1. It does not need treatment or delay surgery; it may pass or become hypothyroidism. Morning cortisol 12.9 is normal. **S**
   - Repeat TSH and free T4 at the visit after surgery.
   - Start levothyroxine only if TSH rises above 10 or free T4 falls, or with symptoms.
3. **Viral upper respiratory infection** (J06.9). Resolved within a week. **S**
   - Problem resolved.
4. **Nicotine dependence, on varenicline** (F17.210). Nine weeks abstinent, which lowers his risk of complications after surgery. **S**
   - Continue varenicline.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Response imaging | After the three cycles before surgery | Completed today | CT five days ago: partial response, no new disease |
| Laboratory | Blood count with neutrophils and platelets | Before surgery | Completed today | Hemoglobin 12.8 (low), white cells 6.2, neutrophils 3.6, platelets 188 |
| Laboratory | Chemistry before surgery: sodium, potassium, calcium, albumin, alkaline phosphatase | Before surgery | Completed today | Sodium 138, potassium 4.3, calcium 9.3, albumin 4.0, alkaline phosphatase 90 |
| Laboratory | Immune-related adverse event laboratory panel: TSH, free T4, liver tests, creatinine and glucose | Before each infusion and after the last dose | Completed today | TSH 6.8 (high) with free T4 1.0: subclinical thyroiditis, grade 1; ALT 31, AST 27, bilirubin 0.6; creatinine 1.1, eGFR 74; glucose 95 |
| Laboratory | Morning cortisol | Baseline and before each immunotherapy infusion (CMID); for symptoms | Completed today | 12.9 mcg/dL at 8 a.m., normal; drawn today as the corrective action for the gap recorded at cycle 2, which closes that deviation with no harm found |
| Imaging | Repeat pulmonary function before surgery | If symptoms or a clinical change after chemotherapy | Not indicated | No new breathlessness, and the values ten weeks ago were well above the thresholds; the surgeon agreed |
| Self-management | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent nine weeks |
| Survey | Distress and depression screening | Every visit; PHQ-9 and GAD-7 at diagnosis and at treatment transitions | Completed today | PHQ-2 1 |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | No cough or breathlessness |
| Examination | Peripheral neuropathy after platinum | Every visit during and after platinum therapy | Completed today | None |
| Self-management | Pulmonary rehabilitation (prehabilitation) | Before lung resection | Completed today | Program of 16 sessions completed |

## Goal progress

- PET-CT, brain MRI, EBUS staging, tissue diagnosis, PD-L1 and comprehensive biomarker results and a tumor board plan within three weeks of the screening CT. Outcome by 1979-05-26: PET-CT in three days, brain MRI in four, EBUS in eight, tumor board in ten; PD-L1 and tissue sequencing back by the consultation, 15 days after the scan. **S**
- Stop smoking completely before treatment starts and stay stopped. In progress; target 1979-09-30. **S**
- Three cycles of chemoimmunotherapy before surgery without a delay of more than one week and without an immune-related adverse event of grade 2 or higher. Outcome by 1979-08-05: Three cycles on schedule; only a grade 1 rise in TSH, monitored without treatment. **S**
- Complete resection (R0) with systematic lymph node dissection within six weeks of the last cycle. In progress; target 1979-09-30. **S**
- Back to walking 3 km most mornings by three months after surgery. In progress; target 1979-09-30. **S**

## Medication changes

- Stopped: Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026), National Comprehensive Cancer Network
- Brunelli A, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e166S-e190S (PMID 23649437) (2013), American College of Chest Physicians
- Howington JA, et al. Treatment of stage I and II non-small cell lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e278S-e313S (PMID 23649443) (2013), American College of Chest Physicians
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology

## Follow-up

- Lobectomy in two weeks. Visit six weeks after surgery with thyroid tests and the pathology. Call for fever, breathlessness or wound problems after the operation. **S**
- Next scheduled visit 1979-09-30: six weeks after left upper lobectomy: pathology, surveillance plan, tobacco remission and pulmonary rehabilitation. **S**
